Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GD2-SADA by Y-mAbs Therapeutics for Solid Tumor: Likelihood of Approval
GD2-SADA is under clinical development by Y-mAbs Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
GD2-SADA by Y-mAbs Therapeutics for Sarcomas: Likelihood of Approval
GD2-SADA is under clinical development by Y-mAbs Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
GD2-SADA by Y-mAbs Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
GD2-SADA is under clinical development by Y-mAbs Therapeutics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
GD2-SADA by Y-mAbs Therapeutics for Melanoma: Likelihood of Approval
GD2-SADA is under clinical development by Y-mAbs Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I...